靶向治疗进展后PD-1免疫治疗在IV期黑色素瘤中的疗效
该回顾性多中心研究纳入99例BRAF+MEK抑制剂进展后的IV期黑色素瘤患者,接受二线免疫检查点阻断(PD-1单药或伊匹木单抗联合纳武利尤单抗)。两组中位无进展生存期、客观缓解率、疾病控制率和中位总生存期均无显著差异,但联合治疗组治疗相关不良事件发生率更高。
要点
- 靶向治疗进展后,PD-1单药与伊匹木单抗联合纳武利尤单抗疗效相似。
- 联合治疗组治疗相关不良事件发生率更高。
- 未发现实验室指标或临床病理特征与二线免疫治疗应答显著相关。
核心结论
- PD-1单药与伊匹木单抗联合纳武利尤单抗在BRAF+MEK抑制剂耐药黑色素瘤中显示相似的活性和结局。
- 联合伊匹木单抗+纳武利尤单抗较单药治疗相关不良事件发生率更高。
研究设计与样本
- 回顾性多中心研究,纳入2015至2019年间9个三级转诊中心中靶向治疗进展后接受二线免疫检查点阻断的IV期黑色素瘤患者99例。
主要发现
- PD-1单药组与伊匹木单抗联合纳武利尤单抗组的中位无进展生存期分别为2.6个月(95%CI 2.0-3.1)和2.0个月(95%CI 1.4-2.6),p=0.15。
- PD-1单药组与联合组的客观缓解率分别为18.0%和15.0%,p=0.70。
- PD-1单药组与联合组的疾病控制率分别为25.7%和18.3%,p=0.39。
- PD-1单药组与联合组的中位总生存期分别为8.4个月(95%CI 5.1-11.7)和7.2个月(95%CI 5.2-9.1),p=0.86。
- 未观察到实验室值或临床病理特征与二线免疫检查点阻断应答显著相关。
临床怎么用
- 对于BRAF+MEK抑制剂进展后的IV期黑色素瘤患者,二线可选择PD-1单药或伊匹木单抗联合纳武利尤单抗,两者疗效相似。
- 选择联合方案时需权衡其更高的治疗相关不良事件发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Targeted therapy (TT) is an effective treatment for advanced BRAFV600-mutated melanoma, but most patients eventually acquire resistance and progress. Here, we evaluated the outcome of second-line immune checkpoint blockade (ICB) after progression on dual BRAF and MEK inhibition. METHODS: Patients with metastatic melanoma progressing on combined BRAF + MEK inhibition and receiving second-line ICB between 2015 and 2019 in 9 tertiary referral centres were enrolled. Demographic and clinical data and blood counts of all patients were collected retrospectively. RESULTS: We identified 99 patients with stage IV melanoma receiving ICB (nivolumab, pembrolizumab [n = 39] or ipilimumab plus nivolumab [n = 60]) after progression on combined TT. The median progression-free survival was similar in the PD-1 and ipilimumab plus nivolumab group (2.6 months [95% confidence interval {CI}, 2.0-3.1] vs. 2.0 [95% CI, 1.4-2.6], p = 0.15). The objective response rate was 18.0% in the PD-1 and 15.0% in the ipilimumab plus nivolumab group (p = 0.70). The disease control rate was 25.7% for monotherapy and 18.3% for combined ICB (p = 0.39). The median overall survival was 8.4 months (95% CI, 5.1-11.7) for patients receiving PD-1 monotherapy and 7.2 months (95% CI, 5.2-9.1) for patients receiving ipilimumab plus nivolumab (p = 0.86). The latter was associated with a higher rate of treatment-related adverse events (AEs). No significant association of laboratory values or clinicopathological characteristics with response to second-line ICB was observed. CONCLUSIONS: PD-1 monotherapy and combined ipilimumab plus nivolumab show similar activity and outcome in patients with melanoma resistant to BRAF + MEK inhibition. However, combined ipilimumab plus nivolumab was associated with a higher rate of treatment-related AEs compared with monotherapy.
引用
- Kreft S, Gesierich A, Eigentler T, et al. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019. PMID: 31212163. doi:10.1016/j.ejca.2019.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。